Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product?
Identifieur interne : 002844 ( Main/Exploration ); précédent : 002843; suivant : 002845Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product?
Auteurs : Jonathon P. Leider [États-Unis] ; Patricia A. R. Brunker [États-Unis] ; Paul M. Ness [États-Unis]Source :
- Transfusion [ 0041-1132 ] ; 2010-06.
English descriptors
- Teeft :
- Acute lung injury, Adverse reaction, Adverse side effects, Allergic reaction, Allograft rejection, Animal models, Antibody, Antibody preparations, Antibody therapeutics, Antibody transfusion, Ards, Argentine hemorrhagic fever, Avian, Blood banks, Blood centers, Body weight, Body weight doses, Broad level, Case reports, Cell lines, Challenge dose, Clade, Clin, Clin microbiol, Clinical disease, Combination therapy, Complete protection, Convalescent, Convalescent blood products, Convalescent plasma, Convalescent plasma therapy, Convalescent plasma transfusion, Convalescent serotherapy, Convalescent transfusion, Critical component, Current pandemic, Darpa, Days postinfection, Distress syndrome, Donor, Dos, Early stages, Effective intervention, Ethical issues, Fresh convalescent plasma, Full protection, Future pandemic, High antibody titers, Homeland security, Hong kong, Human antibodies, Human cases, Human services, Humoral, Humoral response, Hyperimmune globulin, Immune, Immune response, Immune therapy, Immunization, Immunosuppressive effects, Immunotherapy, Index case, Infectious diseases, Influenza, Irrelevant antibody, June, Large scale, Leider, Lethal challenge, Lethal dose, Limited data, Lower doses, Medical countermeasure, Medical countermeasures, Mice prophylaxed, Minnesota center, Moab, Moab injection, Moab preparation, Moab production, Moab strain, Moab therapy, Moabs, Modality, Monoclonal, Monoclonal antibodies, Monoclonal antibody, Mouse, Neutralizing, Neutralizing antibodies, Novel vaccine, Oseltamivir, Pandemic, Pandemic influenza, Pandemic influenza transfusion, Pandemic planning, Pandemic response, Passive immunity, Passive immunization, Passive immunotherapy, Pathogen, Pathogen antibodies, Plasma, Plasma collection, Plo, Positive control, Postinfection, Prophylaxis, Public health, Sars patients, Serotherapy, Serum therapy, Several moab strains, Severe pandemic, Severe reactions, Sheep sera, Survivor, Talecris biotherapeutics, Target antigen, Target ligand, Test prophylaxis, Therapeutic antibodies, Therapeutic test, Trali, Transfusion, Transfusion volume, Treatment options, Undetectable levels, Vaccine, Viral, Viral load, Viral loads, Virus, Virus infection, Wang, Whole blood, Zhou.
Abstract
Due to the potential of a severe pandemic to limit efficacy or availability of medical countermeasures, some researchers have begun a search for new interventions that could complement the planned antiviral‐ and vaccine‐based response to an influenza pandemic. One such countermeasure—the transfusion of pandemic influenza‐specific antibodies from surviving patients to the clinically ill—is the focus of this commentary. Passive immunotherapy, which includes the use of monoclonal antibodies (MoAbs), hyperimmune globulin, or convalescent plasma, had been used before the advent of antibiotics and has recently reentered the limelight due to the accelerating development of MoAb therapies against cancer, a number of microbes, allograft rejection, and a host of other conditions. After the plausible biologic mechanism and somewhat limited data supporting the efficacy for this modality against influenza are reviewed, safety and logistical concerns for utilization of this potential new product (fresh convalescent plasma against influenza [FCP‐Flu]) are discussed. FCP‐Flu could indeed prove useful in a response to a pandemic, but two necessary items must first be satisfied. Most importantly, more research should be conducted to establish FCP‐Flu efficacy against the current and other pandemic strains. Second, and also importantly, blood banks and donor centers should examine whether offering this new product would be feasible in a pandemic and begin planning before a more severe pandemic forces us to respond without adequate preparation.
Url:
DOI: 10.1111/j.1537-2995.2010.02590.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000C34
- to stream Istex, to step Curation: 000C34
- to stream Istex, to step Checkpoint: 000A97
- to stream Main, to step Merge: 002883
- to stream Main, to step Curation: 002844
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product?</title><author><name sortKey="Leider, Jonathon P" sort="Leider, Jonathon P" uniqKey="Leider J" first="Jonathon P." last="Leider">Jonathon P. Leider</name></author><author><name sortKey="Brunker, Patricia A R" sort="Brunker, Patricia A R" uniqKey="Brunker P" first="Patricia A. R." last="Brunker">Patricia A. R. Brunker</name></author><author><name sortKey="Ness, Paul M" sort="Ness, Paul M" uniqKey="Ness P" first="Paul M." last="Ness">Paul M. Ness</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D185C3DFFF547D14BD15736605D42D84B37CF174</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1111/j.1537-2995.2010.02590.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-VXQ1L3FK-W/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000C34</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000C34</idno><idno type="wicri:Area/Istex/Curation">000C34</idno><idno type="wicri:Area/Istex/Checkpoint">000A97</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000A97</idno><idno type="wicri:doubleKey">0041-1132:2010:Leider J:convalescent:transfusion:for</idno><idno type="wicri:Area/Main/Merge">002883</idno><idno type="wicri:Area/Main/Curation">002844</idno><idno type="wicri:Area/Main/Exploration">002844</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product?</title><author><name sortKey="Leider, Jonathon P" sort="Leider, Jonathon P" uniqKey="Leider J" first="Jonathon P." last="Leider">Jonathon P. Leider</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>From the Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; and the Division of Transfusion Medicine, Department of Pathology, The Johns Hopkins Hospital, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Brunker, Patricia A R" sort="Brunker, Patricia A R" uniqKey="Brunker P" first="Patricia A. R." last="Brunker">Patricia A. R. Brunker</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>From the Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; and the Division of Transfusion Medicine, Department of Pathology, The Johns Hopkins Hospital, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Ness, Paul M" sort="Ness, Paul M" uniqKey="Ness P" first="Paul M." last="Ness">Paul M. Ness</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>From the Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; and the Division of Transfusion Medicine, Department of Pathology, The Johns Hopkins Hospital, Baltimore</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Transfusion</title><title level="j" type="alt">TRANSFUSION</title><idno type="ISSN">0041-1132</idno><idno type="eISSN">1537-2995</idno><imprint><biblScope unit="vol">50</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1384">1384</biblScope><biblScope unit="page" to="1398">1398</biblScope><biblScope unit="page-count">15</biblScope><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><date type="published" when="2010-06">2010-06</date></imprint><idno type="ISSN">0041-1132</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0041-1132</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acute lung injury</term><term>Adverse reaction</term><term>Adverse side effects</term><term>Allergic reaction</term><term>Allograft rejection</term><term>Animal models</term><term>Antibody</term><term>Antibody preparations</term><term>Antibody therapeutics</term><term>Antibody transfusion</term><term>Ards</term><term>Argentine hemorrhagic fever</term><term>Avian</term><term>Blood banks</term><term>Blood centers</term><term>Body weight</term><term>Body weight doses</term><term>Broad level</term><term>Case reports</term><term>Cell lines</term><term>Challenge dose</term><term>Clade</term><term>Clin</term><term>Clin microbiol</term><term>Clinical disease</term><term>Combination therapy</term><term>Complete protection</term><term>Convalescent</term><term>Convalescent blood products</term><term>Convalescent plasma</term><term>Convalescent plasma therapy</term><term>Convalescent plasma transfusion</term><term>Convalescent serotherapy</term><term>Convalescent transfusion</term><term>Critical component</term><term>Current pandemic</term><term>Darpa</term><term>Days postinfection</term><term>Distress syndrome</term><term>Donor</term><term>Dos</term><term>Early stages</term><term>Effective intervention</term><term>Ethical issues</term><term>Fresh convalescent plasma</term><term>Full protection</term><term>Future pandemic</term><term>High antibody titers</term><term>Homeland security</term><term>Hong kong</term><term>Human antibodies</term><term>Human cases</term><term>Human services</term><term>Humoral</term><term>Humoral response</term><term>Hyperimmune globulin</term><term>Immune</term><term>Immune response</term><term>Immune therapy</term><term>Immunization</term><term>Immunosuppressive effects</term><term>Immunotherapy</term><term>Index case</term><term>Infectious diseases</term><term>Influenza</term><term>Irrelevant antibody</term><term>June</term><term>Large scale</term><term>Leider</term><term>Lethal challenge</term><term>Lethal dose</term><term>Limited data</term><term>Lower doses</term><term>Medical countermeasure</term><term>Medical countermeasures</term><term>Mice prophylaxed</term><term>Minnesota center</term><term>Moab</term><term>Moab injection</term><term>Moab preparation</term><term>Moab production</term><term>Moab strain</term><term>Moab therapy</term><term>Moabs</term><term>Modality</term><term>Monoclonal</term><term>Monoclonal antibodies</term><term>Monoclonal antibody</term><term>Mouse</term><term>Neutralizing</term><term>Neutralizing antibodies</term><term>Novel vaccine</term><term>Oseltamivir</term><term>Pandemic</term><term>Pandemic influenza</term><term>Pandemic influenza transfusion</term><term>Pandemic planning</term><term>Pandemic response</term><term>Passive immunity</term><term>Passive immunization</term><term>Passive immunotherapy</term><term>Pathogen</term><term>Pathogen antibodies</term><term>Plasma</term><term>Plasma collection</term><term>Plo</term><term>Positive control</term><term>Postinfection</term><term>Prophylaxis</term><term>Public health</term><term>Sars patients</term><term>Serotherapy</term><term>Serum therapy</term><term>Several moab strains</term><term>Severe pandemic</term><term>Severe reactions</term><term>Sheep sera</term><term>Survivor</term><term>Talecris biotherapeutics</term><term>Target antigen</term><term>Target ligand</term><term>Test prophylaxis</term><term>Therapeutic antibodies</term><term>Therapeutic test</term><term>Trali</term><term>Transfusion</term><term>Transfusion volume</term><term>Treatment options</term><term>Undetectable levels</term><term>Vaccine</term><term>Viral</term><term>Viral load</term><term>Viral loads</term><term>Virus</term><term>Virus infection</term><term>Wang</term><term>Whole blood</term><term>Zhou</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Due to the potential of a severe pandemic to limit efficacy or availability of medical countermeasures, some researchers have begun a search for new interventions that could complement the planned antiviral‐ and vaccine‐based response to an influenza pandemic. One such countermeasure—the transfusion of pandemic influenza‐specific antibodies from surviving patients to the clinically ill—is the focus of this commentary. Passive immunotherapy, which includes the use of monoclonal antibodies (MoAbs), hyperimmune globulin, or convalescent plasma, had been used before the advent of antibiotics and has recently reentered the limelight due to the accelerating development of MoAb therapies against cancer, a number of microbes, allograft rejection, and a host of other conditions. After the plausible biologic mechanism and somewhat limited data supporting the efficacy for this modality against influenza are reviewed, safety and logistical concerns for utilization of this potential new product (fresh convalescent plasma against influenza [FCP‐Flu]) are discussed. FCP‐Flu could indeed prove useful in a response to a pandemic, but two necessary items must first be satisfied. Most importantly, more research should be conducted to establish FCP‐Flu efficacy against the current and other pandemic strains. Second, and also importantly, blood banks and donor centers should examine whether offering this new product would be feasible in a pandemic and begin planning before a more severe pandemic forces us to respond without adequate preparation.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Leider, Jonathon P" sort="Leider, Jonathon P" uniqKey="Leider J" first="Jonathon P." last="Leider">Jonathon P. Leider</name></region><name sortKey="Brunker, Patricia A R" sort="Brunker, Patricia A R" uniqKey="Brunker P" first="Patricia A. R." last="Brunker">Patricia A. R. Brunker</name><name sortKey="Ness, Paul M" sort="Ness, Paul M" uniqKey="Ness P" first="Paul M." last="Ness">Paul M. Ness</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002844 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002844 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D185C3DFFF547D14BD15736605D42D84B37CF174
|texte= Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product?
}}
| This area was generated with Dilib version V0.6.33. |  |